<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05005507</url>
  </required_header>
  <id_info>
    <org_study_id>CR109070</org_study_id>
    <secondary_id>2021-002450-81</secondary_id>
    <secondary_id>73763989PAHPB2007</secondary_id>
    <nct_id>NCT05005507</nct_id>
  </id_info>
  <brief_title>A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection</brief_title>
  <acronym>PENGUIN-2</acronym>
  <official_title>A Phase 2, Open-label, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Patients With Chronic Hepatitis B Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy in terms of hepatitis B surface antigen&#xD;
      (HBsAg) changes from baseline for the treatment regimens of 24 weeks of JNJ-73763989 + 24&#xD;
      weeks of nucleos(t)ide analog (NA) + 12 or 24 weeks of pegylated interferon alpha-2a&#xD;
      (PegIFN-alpha-2a) (with immediate or delayed start of PegIFN-alpha-2a treatment).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      JNJ-73763989 (JNJ-3989) is a liver-targeted antiviral therapeutic for subcutaneous injection&#xD;
      designed to treat chronic hepatitis B virus (HBV) infection via a ribonucleic acid&#xD;
      interference (RNAi) mechanism. Combination treatment with JNJ-73763989 and NA has the&#xD;
      potential to specifically decrease HBV viral antigen levels and inhibit viral replication.&#xD;
      Since HBsAg is immune suppressive, the direct reduction of HBsAg levels by JNJ-73763989 is&#xD;
      anticipated to contribute to the restoration of the immune response that is impaired in&#xD;
      chronic HBV infection. Pegylated interferon (PegIFN) is an approved drug for the treatment of&#xD;
      chronic HBV infection and after a finite treatment duration of 48 weeks results in slightly&#xD;
      increased HBsAg seroclearance rates. The primary hypothesis of this study is that at least&#xD;
      one of the combination regimens of JNJ-73763989+NA+PegIFN-alpha-2a is more efficacious than&#xD;
      NA treatment alone (standard of care), as measured by the primary efficacy endpoint. This&#xD;
      study will be conducted in 3 periods: Screening Period (4 weeks), Treatment Period (24 weeks)&#xD;
      and Follow-up (FU) Period (48 weeks), starting at Week 24. Safety assessments will include&#xD;
      adverse events (AEs), serious AEs, clinical safety laboratory tests, electrocardiograms&#xD;
      (ECGs), vital signs, ophthalmologic examinations and physical examinations. Total duration of&#xD;
      individual participation will be up to 76 weeks (including screening period).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 8, 2021</start_date>
  <completion_date type="Anticipated">November 22, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 22, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with a Reduction of at least 2log10 IU/ml in Hepatitis B Surface Antigen (HBsAg) Levels from Baseline at Week 24 (EOSI)</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of participants with a reduction of at least 2 log10 international units per milliliters (IU/mL) in HBsAg levels from baseline at Week 24 (end of study intervention [EOSI]) will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormalities in Clinical Laboratory Tests</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>Percentage of participants with abnormalities in clinical laboratory test (including hematology, blood biochemistry, blood coagulation, urinalysis, urine chemistry, renal biomarkers) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormalities in 12-Lead Electrocardiograms (ECGs)</measure>
    <time_frame>Up to Week 28</time_frame>
    <description>Percentage of participants with abnormalities in 12- lead ECGs (heart rate, PR, QRS and QT corrected [QTc]) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormalities in Vital Signs</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>Percentage of participants with abnormalities in vital signs (systolic blood pressure [SBP], diastolic blood pressure [DBP], and pulse rate) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormalities in Ophthalmologic Examination</measure>
    <time_frame>Week 8</time_frame>
    <description>Percentage of participants with abnormalities in ophthalmologic examination will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormalities in Physical Examination</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of participants with abnormalities in physical examination will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting the Protocol- defined NA Treatment Completion Criteria Based on the Week 24 EOSI or Follow-up (FU) Week 2 Results</measure>
    <time_frame>Week 24 and FU Week 2</time_frame>
    <description>Percentage of participants meeting the protocol-defined NA treatment completion criteria based on the Week 24 (EOSI) or FU Week 2 results will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Hepatitis B Surface Antigen (HBsAg) Seroclearance at Follow-up (FU) Weeks 24 and 48 without Re-starting Nucleos(t)ide Analog (NA) Treatment</measure>
    <time_frame>Follow-up Weeks 24 and 48</time_frame>
    <description>Percentage of participants with HBsAg seroclearance at FU Weeks 24 and 48 (after completion of all study interventions at Week 24) without re-starting NA treatment will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) &lt;lower limit of quantification (LLOQ) at FU Weeks 24 and 48 Without Re-starting NA Treatment</measure>
    <time_frame>Follow-up Weeks 24 and 48</time_frame>
    <description>Percentage of participants with HBV DNA &lt;LLOQ at FU Weeks 24 and 48 (after completion of all study interventions at Week 24) without re-starting NA treatment will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Virologic Flares</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>Percentage of participants with virologic flares will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Biochemical Flares</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>Percentage of participants with biochemical flares will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring NA Re-treatment</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>Percentage of participants requiring NA re-treatment based on failure in NA treatment completion criteria will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBsAg, Hepatitis B e Antigen (HBeAg), HBV DNA, and Alanine Aminotransferase (ALT) Levels Below/Above Different Cut-offs Over Time</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>Percentage of participants with HBsAg, HBeAg, HBV DNA, and ALT levels below/above different cut-offs over time will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HBsAg Seroconversion</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>Percentage of participants with HBsAg seroconversion will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Over Time in HBsAg</measure>
    <time_frame>Baseline up to Week 72</time_frame>
    <description>Change from baseline over time in HBsAg will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve HBsAg Seroclearance/ Seroconversion</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>Time to achieve HBsAg seroclearance/ seroconversion will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve HBV DNA &lt;LLOQ</measure>
    <time_frame>Up to Week 72</time_frame>
    <description>Time to achieve HBV DNA &lt;LLOQ will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Virologic Breakthrough</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Percentage of participants with virologic breakthrough will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of JNJ-73763989 (JNJ-73763924 and JNJ-73763976)</measure>
    <time_frame>Days 1, 29, 85, 113, 169</time_frame>
    <description>Serum samples will be analyzed to determine concentrations of JNJ-73763989 (JNJ-73763924 and JNJ-73763976).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of NA</measure>
    <time_frame>Days 1, 29, 85, 113, 169</time_frame>
    <description>Serum samples will be analyzed to determine concentrations of NA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of PegIFN-alpha-2a</measure>
    <time_frame>Days 1, 29, 85, 113, 169</time_frame>
    <description>Serum samples will be analyzed to determine concentrations of PegIFN-alpha-2a.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Arm 1: JNJ-73763989 + nucleos(t)ide analog (NA) + pegylated interferon alpha-2a (PegIFN-alpha-2a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-73763989 subcutaneous (SC) injection once every 4 weeks for 24 weeks plus NA treatment (either entecavir [ETV], tenofovir disoproxil or tenofovir alafenamide [TAF] tablets orally) once daily for 24 weeks plus PegIFN-alpha-2a SC injection once weekly for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: JNJ-73763989 + NA + PegIFN-alpha-2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-73763989 SC injection once every 4 weeks for 24 weeks plus NA treatment (either ETV, tenofovir disoproxil, or TAF tablets orally) once daily for 24 weeks plus PegIFN-alpha-2a SC injection once weekly from Week 12 till Week 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: JNJ-73763989 + NA + PegIFN-alpha-2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-73763989 SC injection once every 4 weeks for 24 weeks plus NA treatment (either ETV, tenofovir disoproxil or TAF tablets orally) once daily for 24 weeks plus PegIFN-alpha-2a SC injection once weekly from baseline till Week 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-73763989</intervention_name>
    <description>JNJ-73763989 will be administered subcutaneously once every 4 weeks.</description>
    <arm_group_label>Arm 1: JNJ-73763989 + nucleos(t)ide analog (NA) + pegylated interferon alpha-2a (PegIFN-alpha-2a)</arm_group_label>
    <arm_group_label>Arm 2: JNJ-73763989 + NA + PegIFN-alpha-2a</arm_group_label>
    <arm_group_label>Arm 3: JNJ-73763989 + NA + PegIFN-alpha-2a</arm_group_label>
    <other_name>JNJ-3989</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PegIFN-alpha-2a</intervention_name>
    <description>PegIFN-alpha-2a will be administered subcutaneously once weekly.</description>
    <arm_group_label>Arm 1: JNJ-73763989 + nucleos(t)ide analog (NA) + pegylated interferon alpha-2a (PegIFN-alpha-2a)</arm_group_label>
    <arm_group_label>Arm 2: JNJ-73763989 + NA + PegIFN-alpha-2a</arm_group_label>
    <arm_group_label>Arm 3: JNJ-73763989 + NA + PegIFN-alpha-2a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil</intervention_name>
    <description>Tenofovir disoproxil film-coated tablet will be administered orally once daily.</description>
    <arm_group_label>Arm 1: JNJ-73763989 + nucleos(t)ide analog (NA) + pegylated interferon alpha-2a (PegIFN-alpha-2a)</arm_group_label>
    <arm_group_label>Arm 2: JNJ-73763989 + NA + PegIFN-alpha-2a</arm_group_label>
    <arm_group_label>Arm 3: JNJ-73763989 + NA + PegIFN-alpha-2a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAF</intervention_name>
    <description>TAF film-coated tablet will be administered orally once daily.</description>
    <arm_group_label>Arm 1: JNJ-73763989 + nucleos(t)ide analog (NA) + pegylated interferon alpha-2a (PegIFN-alpha-2a)</arm_group_label>
    <arm_group_label>Arm 2: JNJ-73763989 + NA + PegIFN-alpha-2a</arm_group_label>
    <arm_group_label>Arm 3: JNJ-73763989 + NA + PegIFN-alpha-2a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ETV</intervention_name>
    <description>ETV film-coated tablet will be administered orally once daily.</description>
    <arm_group_label>Arm 1: JNJ-73763989 + nucleos(t)ide analog (NA) + pegylated interferon alpha-2a (PegIFN-alpha-2a)</arm_group_label>
    <arm_group_label>Arm 2: JNJ-73763989 + NA + PegIFN-alpha-2a</arm_group_label>
    <arm_group_label>Arm 3: JNJ-73763989 + NA + PegIFN-alpha-2a</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Medically stable based on physical examination, medical history, vital signs, and&#xD;
             12-lead electrocardiogram (ECG) performed at screening&#xD;
&#xD;
          -  Participants must have a body mass index between 18.0 and 35.0 kilograms per meter&#xD;
             square (kg/m^2) inclusive&#xD;
&#xD;
          -  Participants with chronic hepatitis B who should: a) be chronic hepatitis B e antigen&#xD;
             (HBeAg) -negative; b) be anti-HBe antibody-positive; c) be currently receiving&#xD;
             nucleos(t)ide analog (NA) treatment for at least 2 years prior to screening; d) have&#xD;
             serum hepatitis B virus (HBV) deoxyribonucleic acid (DNA) less than (&lt;) 60&#xD;
             international unit/milliliter (IU/mL) on 2 sequential measurements at least 6 months&#xD;
             apart; e) have alanine aminotransferase (ALT) values &lt; 2.0x upper limit of normal&#xD;
             (ULN) on 2 sequential measurements at least 6 months apart&#xD;
&#xD;
          -  Hepatitis B surface antigen (HBsAg) greater than (&gt;) 5 IU/mL at screening&#xD;
&#xD;
          -  Fibroscan liver stiffness measurement less than or equal to (&lt;=) 9.0 kilopascal (kPa)&#xD;
             within 6 months prior to screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or signs of cirrhosis or portal hypertension&#xD;
&#xD;
          -  Evidence of hepatitis A, C, D, E virus infection, or human immunodeficiency virus&#xD;
             (HIV) infection&#xD;
&#xD;
          -  Liver disease of non-HBV etiology&#xD;
&#xD;
          -  Clinically relevant alcohol or drug abuse within 12 months of screening&#xD;
&#xD;
          -  Participants who meet any of the additional exclusion criteria for pegylated&#xD;
             interferon alpha-2a (PegIFN- α2a) as described in local prescribing information&#xD;
             (example, refer to Pegasys SmPC or Pegasys USPI) per the investigator's discretion.&#xD;
             Key exclusion criteria for PegIFN- α2a include: a) Participants with signs or symptoms&#xD;
             compatible with autoimmune disorders. b) Participants with bone marrow suppression. c)&#xD;
             Participants with hypoglycaemia, hyperglycaemia, and/or diabetes mellitus, who cannot&#xD;
             be effectively controlled by medication. d) Participants with pre-existing&#xD;
             ophthalmologic disorders. e) Participants with one or more of the following laboratory&#xD;
             abnormalities: i) Absolute neutrophil count less than (&lt;)1,500 cells/mm3 (&lt;1,000&#xD;
             cells/mm³ for black or African American participants). ii) Serum creatinine &gt;1.5x ULN.&#xD;
             iii) Inadequately controlled thyroid function (thyroid stimulating hormone [TSH] and&#xD;
             thyroxine [T4]). f) Participants with a history of a severe psychiatric disorder&#xD;
             including severe depression, suicidal ideation and attempted suicide, or a current&#xD;
             depression or other psychiatric disorder that is not adequately controlled on a stable&#xD;
             medication regimen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruane Clinical Research Group Inc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Miami Health System</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>I.D. Care, Inc.</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Hepatology Associates</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vancouver ID Research and Care Centre Society</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>GI Research Institute (G.I.R.I.)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima-shi</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kagawa Prefectural Central Hospital</name>
      <address>
        <city>Kagawa</city>
        <zip>760-8557</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital</name>
      <address>
        <city>Kashihara</city>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Musashino Red Cross Hospital</name>
      <address>
        <city>Musashino</city>
        <zip>180-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Nagoya</city>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>PUNKT ZDROWIA Hlebowicz Jakubowski Lekarze sp.p.</name>
      <address>
        <city>Gdansk</city>
        <zip>80405</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne w Lancucie Sp.z o.o.</name>
      <address>
        <city>Lancut</city>
        <zip>37-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>WSS im. dr Wl. Bieganskiego, Oddzial Chorob Zakaznych, Tropikalnych i Pasozytniczych dla Doroslych</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hepid Diagnostyka I Terapia Tomasiewicz, Kiciak - Lekarze Spółka Partnerska</name>
      <address>
        <city>Lublin</city>
        <zip>20-884</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ID Clinic</name>
      <address>
        <city>Mysłowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Zakazny w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <zip>01-201</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>EMC Instytut Medyczny SA</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-220</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ural State Medical University</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454092</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Republic Clinical Infectious Hospital n.a. AF Agafonov</name>
      <address>
        <city>Kazan</city>
        <zip>420140</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk Regional Center For AIDS And Infectious Diseases Treatment And Prophylaxis</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Petersburg City Center for AIDS and Infectious Diseases Treatment and Prophylaxis</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Company Hepatolog Ltd</name>
      <address>
        <city>Samara</city>
        <zip>443045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Smolensk Regional Clinical Hospital</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Infectious Diseases Hospital n. a. S.P. Botkin</name>
      <address>
        <city>St. Petersburg</city>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stavropol State Medical University</name>
      <address>
        <city>Stavropol</city>
        <zip>355017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Clinical Hospital N. 1</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>8003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Vall D Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28032</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Alvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>E-DA Hospital</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>82445</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10500</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiang Mai University Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prince Of Songkla University</name>
      <address>
        <city>Songkla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Manchester General Hospital</name>
      <address>
        <city>Crumpsall</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Alexandra Hospital</name>
      <address>
        <city>Portsmouth</city>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Hong Kong</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 12, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Herpesviridae Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

